ARArmata Pharmaceuticals, Inc. ARMP · AMEX
$3.09 +11.15% (+$0.31)
- Market cap
- $102.4M
- Enterprise value
- $392.4M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 31.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -47.4%
- Gross margin
- 68.2%
- Net margin
- -5,825.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.41
- Free float
- 31.1%
About the company
Armata Pharmaceuticals, Inc. (ARMP) is a biotechnology company focused on developing novel therapeutic options targeting infectious diseases and resistant microorganisms. The company specializes in the use of phage therapy, a method that utilizes bacteriophages, natural predators of bacteria, to combat infections. This innovative technology could offer an alternative to traditional antibiotics, especially in cases of antibiotic resistance. Armata Pharmaceuticals aims to address the challenge of microbial resistance and the need for new treatment approaches. Investors interested in advancements in the treatment of infectious diseases and novel approaches to antibiotic resistance may see potential in Armata Pharmaceuticals, Inc. (ARMP) shares for innovation in the medical industry and improved patient care.
Sector
Healthcare
Industry
Biotechnology
CEO
Deborah L. Birx
Employees
61
Headquarters
Los Angeles
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number